PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34115723-7	2021	The benefit of olaparib and other clinically approved PARP inhibitors has already been demonstrated in several experimental models of human diseases, such as neurodegeneration and neuroinflammation, acute hepatitis, skeletal muscle disorders, aging and acute ischemic stroke, protecting, for example, from the deterioration of the blood-brain barrier, restoring the cellular levels of NAD+, improving mitochondrial function and biogenesis and, among other effects, reducing oxidative stress and pro-inflammatory mediators, such as TNF-alpha, IL1-beta, IL-6 and VCAM1.	olaparib	15-23	interleukin 1 alpha	Homo sapiens	542-550	
34567413-7	2021	Olaparib reduced the inflammation score, the concentration of IL-1beta and IL-6, enhanced the level of IL-10, and decreased the intestinal permeability in TNBS-colitis.	olaparib	0-8	interleukin 1 alpha	Homo sapiens	62-70